Guess what Gilead's up to?
Gilead and Kite are acquiring a new company that will help them expand research and development into cellular therapy. Source - ASPost-Gilead
Trending Content
| +89 | Zoomers are doing life wrong | 28 | 1d | |
| +70 | GF doesn’t care about her looks | 46 | 2h | |
| +52 | How to develop a thick skin? | 22 | 5d | |
| +39 | Insurance as High Finance? | 10 | 1d | |
| +36 | Affair with my Associate… In Desperate Need for Advice | 21 | 5h | |
| +35 | 400k/year in HVAC sales? | 26 | 6h | |
| +32 | Would you rather live alone in an outer borough or with roommates in Manhattan? | 23 | 1d | |
| +31 | Framed Photo of CEO on desk. | 16 | 1d | |
| +24 | BO -> ??? | 14 | 5d | |
| +23 | Why do people listen to Jim Cramer Investing Advice? | 9 | 1h |
Career Resources
Gilead is definitely undervalued at its current price.
Sciences?
Good guess?
I got in Gilead at around $72** a share, and have researched this for quite some time (made a post about the KITE acquisition).
What I love about the stock is 1) Low P/E ratio 2) 2.8% Dividend Yield. They have a PDUFA in February (I believe) for TAF, I believe the stock will rally into it but will sell off; buy the rumour sell the fact. It will be amazing for their HIV revenues.
Gilead has an insane amount of money in hand that's offshore, tax issues can rise here. Another issue is their HCV revenue which have been declining. The real money is in their HIV pipeline (20-25% of the HIV market) which has been growing, their acquisition of KITE (which was a steal) will get them in the Oncology game. Right then and there that's 3 cash flows.
I am very questionable of their HCV revenues though which are pretty bad. Their approval of Sovaldi in China should boost their sales since there is quite a bit of demand from the population
There are many oppurtunities in the market right which are, quite frankly, much better than biotechnology. I am interested to seeing if my thesis plays out in the coming years. If anyone cures HIV, it will be Gilead
.
Are you basing the deal strictly off numbers? I think getting their foot in oncology will be big for them in the future. I try to look at it from a qualitative standpoint.
.
Yeah, I too think they paid a tad too much for Kite.
Quidem excepturi nulla sit rem molestiae. Vel quod doloribus facilis non voluptatibus dolor corporis.
Modi voluptas reprehenderit ut quam harum inventore sunt consequatur. Explicabo suscipit ut nihil corrupti magni et pariatur. Inventore quia quia architecto nisi animi rerum et. Commodi sint ut quis odio. Sunt sit eveniet eos perspiciatis cupiditate.
Possimus nostrum voluptatum ad doloribus quo cumque. Aspernatur maxime voluptatem molestiae sed ipsam aperiam enim. Repellat id ut dolorem accusamus. Blanditiis alias dicta animi in. Provident sit velit nihil perspiciatis voluptate illo. Dolorum reprehenderit praesentium sint pariatur nulla nihil. Adipisci nisi occaecati et voluptate id odio sapiente.
Et sunt asperiores vel dolore nostrum ut. Et sint commodi accusamus quibusdam. Suscipit aperiam amet aspernatur voluptate. Ut ipsa eligendi molestias aut.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...